GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (NAS:LUMO) » Definitions » Cyclically Adjusted Book per Share

Lumos Pharma (Lumos Pharma) Cyclically Adjusted Book per Share : $32.78 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lumos Pharma's adjusted book value per share for the three months ended in Mar. 2024 was $2.151. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $32.78 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Lumos Pharma's average Cyclically Adjusted Book Growth Rate was -3.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lumos Pharma was 10.10% per year. The lowest was 3.80% per year. And the median was 6.95% per year.

As of today (2024-06-08), Lumos Pharma's current stock price is $2.48. Lumos Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $32.78. Lumos Pharma's Cyclically Adjusted PB Ratio of today is 0.08.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lumos Pharma was 1.21. The lowest was 0.07. And the median was 0.27.


Lumos Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Lumos Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Cyclically Adjusted Book per Share Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.35 29.47 32.34 33.86 32.97

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.91 33.79 33.65 32.97 32.78

Competitive Comparison of Lumos Pharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Lumos Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's Cyclically Adjusted PB Ratio falls into.



Lumos Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lumos Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.151/131.7762*131.7762
=2.151

Current CPI (Mar. 2024) = 131.7762.

Lumos Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 23.415 100.560 30.684
201409 22.682 100.428 29.762
201412 63.344 99.070 84.256
201503 73.481 99.621 97.199
201506 70.890 100.684 92.782
201509 64.873 100.392 85.154
201512 61.149 99.792 80.747
201603 55.137 100.470 72.317
201606 46.409 101.688 60.141
201609 42.778 101.861 55.341
201612 39.954 101.863 51.687
201703 35.222 102.862 45.123
201706 31.536 103.349 40.210
201709 30.593 104.136 38.713
201712 36.756 104.011 46.568
201803 33.407 105.290 41.811
201806 30.230 106.317 37.469
201809 29.550 106.507 36.561
201812 27.819 105.998 34.584
201903 25.839 107.251 31.748
201906 23.811 108.070 29.034
201909 20.839 108.329 25.349
201912 -14.338 108.420 -17.427
202003 14.656 108.902 17.734
202006 14.043 108.767 17.014
202009 14.293 109.815 17.151
202012 14.036 109.897 16.830
202103 13.078 111.754 15.421
202106 12.100 114.631 13.910
202109 11.262 115.734 12.823
202112 10.647 117.630 11.927
202203 9.788 121.301 10.633
202206 8.898 125.017 9.379
202209 8.084 125.227 8.507
202212 7.207 125.222 7.584
202303 6.418 127.348 6.641
202306 5.430 128.729 5.559
202309 4.484 129.860 4.550
202312 3.370 129.419 3.431
202403 2.151 131.776 2.151

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Lumos Pharma  (NAS:LUMO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lumos Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.48/32.78
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lumos Pharma was 1.21. The lowest was 0.07. And the median was 0.27.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lumos Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (Lumos Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.
Executives
David B Karpf officer: Chief Medical Officer 1360 WILLOW ROAD #100, MENLO PARK CA 94025
Aaron Schuchart officer: Chief Business Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250, AUSTIN TX 78746
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Joseph S Mccracken director C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Richard J Hawkins director, officer: Chief Executive Officer 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Emmett Cunningham director C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Kevin M. Lalande director 201 WEST 5TH STREET, AUSTIN TX 78701
John C. Mckew officer: Chief Scientific Officer C/O LUMOS PHARMA, 4200 MARATHON BLVD, STE 200, AUSTIN TX 78756
Deerfield Mgmt Iii, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iii, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Bradley J Powers officer: Principal Executive Officer C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Lori D Lawley officer: Principal Accounting Officer C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Ernest Iii Talarico director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010